Professor Pandha qualified as a doctor at the University of Birmingham and has trained in internal medicine and subsequently in medical oncology at the Royal Postgraduate Medical School, Hammersmith Hospital. He spent four years in research at the CRUK labs at the Hammersmith to gain his PhD in gene therapy, for which he was awarded the McElwain prize. He completed his training at Stanford University in the USA and the Royal Marsden Hospital in London. He was a consultant medical oncologist at St Georges University of London in 2000 before his appointment as Professor of Medical Oncology at Surrey University in 2006. He has been director of the Surrey Cancer Research Institute (SCRI) since 2014.
Professor Pandha specialises in the treatment of prostate, kidney and bladder cancer, and advises a number of companies in early phase clinical trials of experimental cancer treatments in these fields. As a full professor at the University of Surrey, he leads a group of 22 scientists, doctors, nurses, technicians and research students. His research focuses on the development of new cancer biomarkers, new cancer therapies using the immune system (immunotherapy, cancer vaccines), live viruses (viral therapy) and small molecules. His group is particularly interested in the family of HOX genes, which normally control limb and organ growth in the embryo, but which drive cancer cell growth in adults. His team discovered the new test for prostate and bladder cancers, called EN2, a member of this HOX gene family, which is now undergoing final evaluation.
Professor Pandha has published over 200 scientific papers and contributed to 14 medical textbooks. He has been a member of advisory boards in the management of urological cancers and on the editorial board of several medical journals.